Financial News

Articles published by Curevo Vaccine

Curevo Enrolls First Participants in Phase 2 Extension Trial

June 02, 2025

From Curevo Vaccine

Via GlobeNewswire

Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

March 17, 2025

From Curevo Vaccine

Via GlobeNewswire

Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

January 12, 2025

From Curevo Vaccine

Via GlobeNewswire

Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

From Curevo Vaccine

Via GlobeNewswire

Curevo Presents Positive Shingles Vaccine Outcomes Data

October 31, 2024

From Curevo Vaccine

Via GlobeNewswire

Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week

October 16, 2024

From Curevo Vaccine

Via GlobeNewswire

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

April 08, 2024

From Curevo Vaccine

Via GlobeNewswire

Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix

January 07, 2024

From Curevo Vaccine

Via GlobeNewswire

Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference

December 21, 2023

From Curevo Vaccine

Via GlobeNewswire

Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer

April 11, 2023

From Curevo Vaccine

Via GlobeNewswire

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

November 16, 2022

From Curevo Vaccine

Via Business Wire

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

February 10, 2022

From Curevo Vaccine

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Financial News

Articles published by Curevo Vaccine

Popular Pages